Search

Your search keyword '"Bug G"' showing total 374 results
Start Over Author "Bug G"
374 results on '"Bug G"'

1. REAL-WORLD DATA SUGGEST EFFECTIVNESS OF THE ALLOGENEIC MESENCHYMAL STROMAL CELLS PREPARATION MSC-FFM IN RUXOLITINIB-REFRACTORY OR -INTOLERANT ACUTE GRAFT-VERSUS-HOST DISEASE

Author

Pfeffermann, L., primary, Boenig, H.B., additional, Verbeek, M., additional, Herhaus, P., additional, Braitsch, K., additional, Beutel, G., additional, Schmid, C., additional, Muller, N., additional, Bug, G., additional, Döring, M., additional, von Stackelberg, A., additional, Tischer, J., additional, Ayuk, F., additional, Wulf, G., additional, Holtick, U., additional, Jahrsdorfer, B., additional, Schrezenmeier, H., additional, Kuci, S., additional, Kuci, Z., additional, Zens, A., additional, Tribanek, M., additional, Zeiser, R., additional, Huenecke, S., additional, and Bader, P., additional

Published
2024
Full Text
View/download PDF

3. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT

Author

Saraceni, F., Labopin, M., Raiola, A. M., Blaise, D., Remenyi, P., Sora', Federica, Pavlu, J., Bramanti, S., Busca, A., Berceanu, A., Battipaglia, G., Visani, G., Socie, G., Bug, G., Mico, C., La Nasa, G., Musso, M., Olivieri, A., Spyridonidis, A., Savani, B., Ciceri, F., Nagler, A., Mohty, M., Sora' F. (ORCID:0000-0002-9607-5298), Saraceni, F., Labopin, M., Raiola, A. M., Blaise, D., Remenyi, P., Sora', Federica, Pavlu, J., Bramanti, S., Busca, A., Berceanu, A., Battipaglia, G., Visani, G., Socie, G., Bug, G., Mico, C., La Nasa, G., Musso, M., Olivieri, A., Spyridonidis, A., Savani, B., Ciceri, F., Nagler, A., Mohty, M., and Sora' F. (ORCID:0000-0002-9607-5298)

Abstract

We conducted a registry analysis including adult acute myeloid leukemia (AML) patients in remission who had received thiotepa, busulfan, and fludarabine (TBF) or treosulfan-based (Treo) conditioning for haplo-hematopoietic stem cell transplant (HSCT) with posttransplant cyclophosphamide (PTCy) between 2010 and 2020. A total of 1123 patients met the inclusion criteria (968 received TBF and 155 received Treo). A 1:1 matched-pair analysis was performed on 142 TBF and 142 Treo patients. In the Treo group, 68% of patients received treosulfan at a dose ≥36 g/m2 and 54% of patients received a second alkylator (thiotepa or melphalan). We observed a trend toward increased incidence of grade II-IV acute (a) graft-versus-host disease (GVHD) at 180 days in the TBF group compared with Treo (29% versus 20%; P = 0.08), while incidence of grade III-IV aGVHD was not statistically different. Similarly, the incidence of chronic (c) GVHD was not statistically different in the 2 groups. Incidence of nonrelapse mortality at 2 years was 19% in TBF and 14% in Treo (P = 0.4). Relapse incidence at 2 years was not statistically different in the 2 groups (16% and 18% in TBF and Treo, respectively; P = 0.9). Leukemia-free survival, overall survival, and GVHD-free, relapse-free survival was 65% versus 68% (P = 0.6), 73% versus 76% (P = 0.5), and 54% versus 53% (P = 0.8) in TBF versus Treo, respectively. In conclusion, we did not find a significant difference between the 2 conditioning in the present study; Treo and TBF represent 2 valid alternative regimens for haplo-HSCT with PTCy for AML in remission.

Published
2023

4. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

Author

Thol, F, Klesse, S, Köhler, L, Gabdoulline, R, Kloos, A, Liebich, A, Wichmann, M, Chaturvedi, A, Fabisch, J, Gaidzik, V I, Paschka, P, Bullinger, L, Bug, G, Serve, H, Göhring, G, Schlegelberger, B, Lübbert, M, Kirchner, H, Wattad, M, Kraemer, D, Hertenstein, B, Heil, G, Fiedler, W, Krauter, J, Schlenk, R F, Döhner, K, Döhner, H, Ganser, A, and Heuser, M

Published
2017
Full Text
View/download PDF

5. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

Author

Mossner, M, Jann, J-C, Nowak, D, Platzbecker, U, Giagounidis, A, Götze, K, Letsch, A, Haase, D, Shirneshan, K, Braulke, F, Schlenk, R F, Haferlach, T, Schafhausen, P, Bug, G, Lübbert, M, Ganser, A, Büsche, G, Schuler, E, Nowak, V, Pressler, J, Obländer, J, Fey, S, Müller, N, Lauinger-Lörsch, E, Metzgeroth, G, Weiß, C, Hofmann, W-K, Germing, U, and Nolte, F

Published
2016
Full Text
View/download PDF

6. Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

Author

Middeke, J M, Herbst, R, Parmentier, S, Bug, G, Hänel, M, Stuhler, G, Schäfer-Eckart, K, Rösler, W, Klein, S, Bethge, W, Bitz, U, Büttner, B, Knoth, H, Alakel, N, Schaich, M, Morgner, A, Kramer, M, Sockel, K, von Bonin, M, Stölzel, F, Platzbecker, U, Röllig, C, Thiede, C, Ehninger, G, Bornhäuser, M, and Schetelig, J

Published
2016
Full Text
View/download PDF

9. Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia

Author

Schmid, C., Labopin, M., Schaap, N.P., Veelken, H., Brecht, A., Stadler, M., Finke, J., Baron, F., Collin, M., Bug, G., Ljungman, P., Blaise, D., Tischer, J., Bloor, A., Kulagin, A., Giebel, S., Gorin, N.C., Esteve, J., Ciceri, F., Savani, B., Nagler, A., Mohty, M., Schmid, C., Labopin, M., Schaap, N.P., Veelken, H., Brecht, A., Stadler, M., Finke, J., Baron, F., Collin, M., Bug, G., Ljungman, P., Blaise, D., Tischer, J., Bloor, A., Kulagin, A., Giebel, S., Gorin, N.C., Esteve, J., Ciceri, F., Savani, B., Nagler, A., and Mohty, M.

Abstract

Item does not contain fulltext, We report on 318 patients with acute leukemia, receiving donor lymphocyte infusion (DLI) in complete hematologic remission (CHR) after allogeneic stem cell transplantation (alloSCT). DLI were applied preemptively (preDLI) for minimal residual disease (MRD, n = 23) or mixed chimerism (MC, n = 169), or as prophylaxis in high-risk patients with complete chimerism and molecular remission (proDLI, n = 126). Median interval from alloSCT to DLI1 was 176 days, median follow-up was 7.0 years. Five-year cumulative relapse incidence (CRI), non-relapse mortality (NRM), leukemia-free and overall survival (LFS/OS) of the entire cohort were 29.1%, 12.7%, 58.2%, and 64.3%. Cumulative incidences of acute graft-versus-host disease (aGvHD) grade II-IV°/chronic GvHD were 11.9%/31%. Nineteen patients (6%) died from DLI-induced GvHD. Age ≥60 years (p = 0.046), advanced stage at transplantation (p = 0.003), shorter interval from transplantation (p = 0.018), and prior aGvHD ≥II° (p = 0.036) were risk factors for DLI-induced GvHD. GvHD did not influence CRI, but was associated with NRM and lower LFS/OS. Efficacy of preDLI was demonstrated by decreasing MRD/increasing blood counts in 71%, and increasing chimerism in 70%. Five-year OS after preDLI for MRD/MC was 51%/68% among responders, and 37% among non-responders. The study describes response and outcome of DLI in CHR and helps to identify candidates without increased risk of severe GvHD.

Published
2022

10. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Author

Loke, J., Labopin, M., Craddock, C., Cornelissen, J.J.L.M, Labussière-Wallet, H., Wagner-Drouet, E.M., Gorkom, G. van, Schaap, N.P.M., Kröger, N.M., Veelken, J.H., Rovira, M., Menard, A.L., Bug, G., Bazarbachi, A., Giebel, S., Brissot, E., Nagler, A., Esteve, J., Mohty, M., Loke, J., Labopin, M., Craddock, C., Cornelissen, J.J.L.M, Labussière-Wallet, H., Wagner-Drouet, E.M., Gorkom, G. van, Schaap, N.P.M., Kröger, N.M., Veelken, J.H., Rovira, M., Menard, A.L., Bug, G., Bazarbachi, A., Giebel, S., Brissot, E., Nagler, A., Esteve, J., and Mohty, M.

Abstract

Contains fulltext : 282630.pdf (Publisher’s version ) (Open Access), BACKGROUND: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort. METHODS: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation. RESULTS: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.1%; 95% confidence interval [CI], 26.7-43.7) as compared to the cohort without (n = 601) (64%; 95% CI, 59.1-68.4; P = .001). In patients with mutant TP53 AML with no evidence of either chromosome 17p loss (17p-) and/or complex karyotype (CK) (n = 53, 29.6%), 2-year OS was 65.2% (95% CI, 48.4-77.6). This was not significantly different to patients without TP53 mutations. In patients with mutant TP53 AML with either 17p- and/or CK (n = 126, 70.4%), the OS was lower (24.6%; 95% CI, 16.2-34; P = .001). CONCLUSIONS: In summary, the adverse prognostic effect of TP53 mutations in AML following an allo-SCT is not evident in patients with neither co-occurring 17p- and/or CK, and these data inform decisions regarding allo-SCT in patients with TP53 mutant AML.

Published
2022

12. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Author

Zeiser, R, Burchert, A, Lengerke, C, Verbeek, M, Maas-Bauer, K, Metzelder, S K, Spoerl, S, Ditschkowski, M, Ecsedi, M, Sockel, K, Ayuk, F, Ajib, S, de Fontbrune, F S, Na, I-K, Penter, L, Holtick, U, Wolf, D, Schuler, E, Meyer, E, Apostolova, P, Bertz, H, Marks, R, Lübbert, M, Wäsch, R, Scheid, C, Stölzel, F, Ordemann, R, Bug, G, Kobbe, G, Negrin, R, Brune, M, Spyridonidis, A, Schmitt-Gräff, A, van der Velden, W, Huls, G, Mielke, S, Grigoleit, G U, Kuball, J, Flynn, R, Ihorst, G, Du, J, Blazar, B R, Arnold, R, Kröger, N, Passweg, J, Halter, J, Socié, G, Beelen, D, Peschel, C, Neubauer, A, Finke, J, Duyster, J, and von Bubnoff, N

Published
2015
Full Text
View/download PDF

14. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients (Bone Marrow Transplantation, (2020), 55, 6, (1114-1125), 10.1038/s41409-020-0803-y)

Author

Spyridonidis A., Labopin M., Savani B. N., Niittyvuopio R., Blaise D., Craddock C., Socie G., Platzbecker U., Beelen D., Milpied N., Cornelissen J. J., Ganser A., Huynh A., Griskevicius L., Giebel S., Aljurf M., Brissot E., Malard F., Esteve J., Peric Z., Baron F., Ruggeri A., Schmid C., Gilleece M., Gorin N. -C., Lanza F., Shouval R., Versluis J., Bug G., Floisand Y., Ciceri F., Sanz J., Bazarbachi A., Nagler A., Mohty M., Spyridonidis, A., Labopin, M., Savani, B. N., Niittyvuopio, R., Blaise, D., Craddock, C., Socie, G., Platzbecker, U., Beelen, D., Milpied, N., Cornelissen, J. J., Ganser, A., Huynh, A., Griskevicius, L., Giebel, S., Aljurf, M., Brissot, E., Malard, F., Esteve, J., Peric, Z., Baron, F., Ruggeri, A., Schmid, C., Gilleece, M., Gorin, N. -C., Lanza, F., Shouval, R., Versluis, J., Bug, G., Floisand, Y., Ciceri, F., Sanz, J., Bazarbachi, A., Nagler, A., and Mohty, M.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020

25. Current practice in nutrition after allogeneic hematopoietic stem cell transplantation – Results from a survey among hematopoietic stem cell transplant centers

Author

Toenges, R., primary, Greinix, H., additional, Lawitschka, A., additional, Halter, J., additional, Baumgartner, A., additional, Simon, A., additional, Arends, J., additional, Jäger, P., additional, Middeke, M., additional, Hilgendorf, I., additional, Klein, S., additional, Wagner-Drouet, E.M., additional, Schmid, C., additional, Bug, G., additional, and Wolff, D., additional

Published
2021
Full Text
View/download PDF

26. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails

Author

Schetelig, J., Baldauf, H., Heidenreich, F., Massalski, C., Frank, S., Sauter, J., Stelljes, M., Ayuk, F.A., Bethge, W.A., Bug, G., Klein, S., Wendler, S., Lange, V., Wreede, L.C. de, Furst, D., Kobbe, G., Ottinger, H.D., Beelen, D.W., Mytilineos, J., Fleischhauer, K., Schmidt, A.H., Bomhauser, M., German Cooperative Transp, and Deutsch Register Stammzelltransp

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Genotype, Immunobiology and Immunotherapy, medicine.medical_treatment, Immunology, Medizin, Graft vs Host Disease, Human leukocyte antigen, Hematopoietic stem cell transplantation, Biochemistry, Donor Selection, Young Adult, Receptors, KIR, Internal medicine, medicine, Humans, Transplantation, Homologous, Cumulative incidence, Aged, Proportional Hazards Models, Retrospective Studies, Donor selection, Proportional hazards model, business.industry, Hazard ratio, Hematopoietic Stem Cell Transplantation, Receptors, KIR3DL1, Cell Biology, Hematology, Middle Aged, Transplantation, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Female, Unrelated Donors, business, KIR3DL1
Abstract

Several studies suggest that harnessing natural killer (NK) cell reactivity mediated through killer cell immunoglobulin-like receptors (KIRs) could reduce the risk of relapse after allogeneic hematopoietic cell transplantation. Based on one promising model, information on KIR2DS1 and KIR3DL1 and their cognate ligands can be used to classify donors as KIR-advantageous or KIR-disadvantageous. This study was aimed at externally validating this model in unrelated donor hematopoietic cell transplantation. The impact of the predictor on overall survival (OS) and relapse incidence was tested in a Cox regression model adjusted for patient age, a modified disease risk index, Karnofsky performance status, donor age, HLA match, sex match, cytomegalovirus match, conditioning intensity, type of T-cell depletion, and graft type. Data from 2222 patients with acute myeloid leukemia or myelodysplastic syndrome were analyzed. KIR genes were typed by using high-resolution amplicon-based next-generation sequencing. In univariable analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients with a KIR-advantageous donor were comparable to patients with a KIR-disadvantageous donor. The adjusted hazard ratio from the multivariable Cox regression model was 0.99 (Wald test, P = .93) for OS and 1.04 (Wald test, P = .78) for relapse incidence. We also tested the impact of activating donor KIR2DS1 and inhibition by KIR3DL1 separately but found no significant impact on OS and the risk of relapse. Thus, our study shows that the proposed model does not universally predict NK-mediated disease control. Deeper knowledge of NK-mediated alloreactivity is necessary to predict its contribution to graft-versus-leukemia reactions and to eventually use KIR genotype information for donor selection.

Published
2020
Full Text
View/download PDF

27. Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

Author

Bazarbachi A, Schmid C, Labopin M, Beelen D, Wolfgang Blau I, Potter V, Niittyvuopio R, Socié G, Blaise D, Sanz J, Ciceri F, Abou Dalle I, Spyridonidis A, Bug G, Esteve J, Savani BN, Nagler A, and Mohty M

Subjects
surgical procedures, operative, endocrine system diseases, hemic and lymphatic diseases, neoplasms
Abstract

Relapsed acute myeloid leukemia (AML) post allogeneic-hematopoietic-cell-transplantation (allo-HCT) has a dismal prognosis.

Published
2020

28. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Bazarbachi, A., Bug, G. (Gesine), Baron, F. (Frederic), Brissot, E, Ciceri, F, Abou Dalle, I., Döhner, H. (Hartmut), Esteve, J. (Jordi), Floisand, Y., Giebel, S. (Sebastian), Gilleece, M., Gorin, N.C., Jabbour, J. (Jason), Aljurf, M, Kantarjian, H. (Hagop), Kharfan-Dabaja, M., Labopin, M. (Myriam), Lanza, F. (Francesco), Malard, F, Peric, Z., Prebet, T. (Thomas), Ravandi, F, Ruggeri, A. (Annelisa), Sanz, J. (Jaime), Schmid, C. (Christoph), Shouval, R, Spyridonidis, A., Versluis, J., Vey, N. (Norbert), Savani, BN, Nagler, A. (Arnon), Mohty, M. (Mohamad), Bazarbachi, A., Bug, G. (Gesine), Baron, F. (Frederic), Brissot, E, Ciceri, F, Abou Dalle, I., Döhner, H. (Hartmut), Esteve, J. (Jordi), Floisand, Y., Giebel, S. (Sebastian), Gilleece, M., Gorin, N.C., Jabbour, J. (Jason), Aljurf, M, Kantarjian, H. (Hagop), Kharfan-Dabaja, M., Labopin, M. (Myriam), Lanza, F. (Francesco), Malard, F, Peric, Z., Prebet, T. (Thomas), Ravandi, F, Ruggeri, A. (Annelisa), Sanz, J. (Jaime), Schmid, C. (Christoph), Shouval, R, Spyridonidis, A., Versluis, J., Vey, N. (Norbert), Savani, BN, Nagler, A. (Arnon), and Mohty, M. (Mohamad)

Abstract

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML). Because of the poor prognosis associated with FLT3-internal tandem duplication mutated AML, allogeneic hematopoietic stem-cell transplantation (SCT) was commonly performed in first complete remission. Remarkable progress has been made in frontline treatments with the incorporation of FLT3 inhibitors and the development of highly sensitive minimal/measurable residual disease assays. Similarly, recent progress in allogeneic hematopoietic SCT includes improvement of transplant techniques, the use of haplo-identical donors in patients lacking an HLA matched donor, and the introduction of FLT3 inhibitors as post-transplant maintenance therapy. Nevertheless, current transplant strategies vary between centers and differ in terms of transplant indications based on the internal tandem duplication allelic ratio and concomitant nucleophosmin-1 mutation, as well as in terms of post-transplant maintenance/consolidation. This review generated by international leukemia or transplant experts, mostly from the European Society for Blood and Marrow Transplantation, attempts to develop a position statement on best approaches for allogeneic hematopoietic SCT for AML with FLT3-internal tandem duplication including indications for and modalities of such transplants and on the potential optimization of post-transplant maintenance with FLT inhibitors.

Published
2020
Full Text
View/download PDF

29. Evaluation of pregnancies after allogeneic stem cell transplantation during the last 15years in Germany

Author

Sockel, K., Frank, S., Neu, A., Ditschkowski, M., Hilgendorf, I., Goeckenjan, M., Stoelzel, F., Middeke, J. M., Kroeger, N., Ayuketang, Ayuk F., Eder, M., Bethge, W., Finke, J., Bertz, H., Kobbe, G., Kaufmann, M., Platzbecker, U., Beverungen, D., Schmid, C., von Bonin, M., Heberling, L., Teipel, R., Bug, G., Fraccaroli, A., Tischer, J., Holler, B., Wolff, D., Luft, T., Roesler, W., Schaefer-Eckart, K., Dressler, S., Scheid, C., Holtick, U., Klein, S., Blau, I. -W., Burchert, A., Wulf, G., Hasenkamp, J., Kaun, S., Wittke, C., Wortmann, F., Bornhaeuser, M., Schetelig, J., Sockel, K., Frank, S., Neu, A., Ditschkowski, M., Hilgendorf, I., Goeckenjan, M., Stoelzel, F., Middeke, J. M., Kroeger, N., Ayuketang, Ayuk F., Eder, M., Bethge, W., Finke, J., Bertz, H., Kobbe, G., Kaufmann, M., Platzbecker, U., Beverungen, D., Schmid, C., von Bonin, M., Heberling, L., Teipel, R., Bug, G., Fraccaroli, A., Tischer, J., Holler, B., Wolff, D., Luft, T., Roesler, W., Schaefer-Eckart, K., Dressler, S., Scheid, C., Holtick, U., Klein, S., Blau, I. -W., Burchert, A., Wulf, G., Hasenkamp, J., Kaun, S., Wittke, C., Wortmann, F., Bornhaeuser, M., and Schetelig, J.

Published
2020

30. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Bazarbachi, A, Bug, G, Baron, F, Brissot, E, Ciceri, F, Abou Dalle, I, Dohner, H, Esteve, J, Floisand, Y, Giebel, S, Gilleece, M, Gorin, NC, Jabbour, E, Aljurf, M, Kantarjian, H, Kharfan-Dabaja, M, Labopin, M, Lanza, F, Malard, F, Peric, Z, Prebet, T, Ravandi, F, Ruggeri, A, Sanz, J, Schmid, C, Shouval, R, Spyridonidis, A, Versluis, Jurjen, Vey, N, Savani, BN, Nagler, A, Mohty, M, Bazarbachi, A, Bug, G, Baron, F, Brissot, E, Ciceri, F, Abou Dalle, I, Dohner, H, Esteve, J, Floisand, Y, Giebel, S, Gilleece, M, Gorin, NC, Jabbour, E, Aljurf, M, Kantarjian, H, Kharfan-Dabaja, M, Labopin, M, Lanza, F, Malard, F, Peric, Z, Prebet, T, Ravandi, F, Ruggeri, A, Sanz, J, Schmid, C, Shouval, R, Spyridonidis, A, Versluis, Jurjen, Vey, N, Savani, BN, Nagler, A, and Mohty, M

Published
2020

35. Data from the German-Austrian-Suisse MDS registry (D-A-CH MDS registry): V954

Author

Germing, U., Giagounidis, A. A., Aul, C., Kündgen, A., Haase, D., Schanz, J., Pfeilstöcker, M., Noesslinger, T., Platzbecker, U., Götze, K., Lübbert, M., Blum, S., Hildebrandt, B., Valent, P., Krieger, O., Stauder, R., Hofmann, W.-K., Braess, J., Schulte, K., Kreutzer, K.-A., Büsche, G., Kreipe, H., Stadler, M., Ganser, A., Schlenk, R., Meckenstock, G., Bug, G., Runde, V., Haas, R., Tüchler, H., Lauseker, M., Hasford, J., and Gattermann, N.

Published
2011

48. Outcome and Risk Factor Analysis in 173 Patients with AML and MDS with Poor Risk Cytogenetics Receiving a Uniform Conditioning Regimen for Allogeneic Stem Cell Transplantation (SCT): V546

Author

Pfeiffer, T., Schleuning, M., Eder, M., Braess, J., Baurmann, H., Bunjes, D., Holler, E., Kolbe, K., Greinix, H., Krejci, M., Stelljes, M., Gerbitz, A., Christopeit, M., Bug, G., Scheid, C., Bethge, W. A., Mayer, J., Dammann, E., v. Harsdorf, S., Meyer, R., Schlimok, G., Schwerdtfeger, R., Ganser, A., Kolb, H.-J., and Schmid, C.

Published
2009

Catalog

Books, media, physical & digital resources
See catalog results